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Abstract
Bortezomib is a novel anti-cancer agent which has shown promising activity in non-small lung
cancer (NSCLC) patients. However, only a subset of patients respond to this treatment. We show
that NSCLC cell lines are differentially sensitive to bortezomib, IC50 values ranging from 5 to 83
nM. The apoptosis-inducing potential of bortezomib in NSCLC cells was found to be dependent
not only on the apoptotic phenotype but also on the proteasomal phenotype of individual cell lines.
Upon effective proteasome inhibition, H460 cells were more susceptible to apoptosis induction by
bortezomib than SW1573 cells, indicating a different apoptotic phenotype. However, exposure to
a low dose of bortezomib did only result in SW1573 cells, and not in H460 cells, in inhibition of
proteasome activity and subsequent apoptosis. This suggests a different proteasomal phenotype as
well. Additionally, overexpression of anti-apoptotic protein Bcl-2 in H460 cells did not affect the
proteasomal phenotype of H460 cells but did result in decreased bortezomib-induced apoptosis.
In conclusion, successful proteasome-inhibitor based treatment strategies in NSCLC face the
challenge of having to overcome apoptosis resistance as well as proteasomal resistance of individual
lung cancer cells. Further studies in NSCLC are warranted to elucidate underlying mechanisms.
Findings
Intracellular protein metabolism involves both synthesis
as well as degradation of proteins. The vast majority of
proteins is selectively degraded by the ubiquitin-proteas-
ome system (UPS). The 26S proteasome complex is com-
posed of a 20S "core", a large protein complex that
harbours the proteolytically active sites, and 19S "caps",
which play a role in the recognition of poly-ubiquitinated
protein substrates, targeted for degradation. Poly-ubiqui-
tination involves covalent ligation of the target protein, by
the sequential action of three enzymes, to a chain of ubiq-
uitin molecules [1].
Growing awareness of the pivotal role of the UPS in nor-
mal cell physiology as well as in (malignant) disease pro-
pelled the development of proteasome inhibitors for
therapeutic applications [2-4]. Bortezomib (Velcade) is
the first clinically approved small molecule proteasome
inhibitor. It reversibly binds and inhibits the chymotryp-
tic-like proteolytic activity of the proteasome, localized
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within the β5 subunit of the 20S core. This results in dis-
turbance of intracellular protein homeostasis by accumu-
lation of poly-ubiquitinated proteins. Among other
effects, this can trigger apoptosis, with a relative selectivity
for malignant as opposed to normal cells [3].
Lung cancer is the most common cause of cancer-related
death in the world [5]. Non-small cell lung cancer
(NSCLC) consists of epithelial tumors, accounting for
approximately 80% of lung carcinomas. Clinical studies
showed promising activity of bortezomib in a subset of
patients with non-small cell lung cancer (NSCLC) [6,7].
So far the exact molecular mechanism of resistance of
NSCLC to bortezomib remains unclear [8-11]. Recently,
adaptation of leukaemia and lymphoma cells to continu-
ous exposure of bortezomib was reported to result from
increased expression and altered subunit composition of
the proteasome [12,13]. Furthermore, resistance was
shown to be associated with increased expression of anti-
apoptotic Bcl-2 family member proteins and heat shock
proteins [14-17]. In this study, we examined the effects of
bortezomib in a panel of NSCLC cell lines. We observed
differential activity of bortezomib in NSCLC cells regard-
ing growth inhibition, the proteasome activity profile and
apoptosis induction.
We first determined the anti-proliferative effect of a con-
centration range of bortezomib by MTT assay in a panel of
NSCLC cell lines (Figure 1A). We observed differential
sensitivity to bortezomib-induced growth inhibition, with
IC50 values ranging from 5 to 83 nM. The p53 status did
not correlate with sensitivity (Figure 1B). Next, to estab-
lish the apoptosis inducing potential of bortezomib, a
sensitive cell line, SW1573, and a resistant cell line, H460,
were selected for treatment and subsequent PI staining-
based FACS analysis to determine the subG1 apoptotic
fraction of the cell population. Additionally, the fractions
of cells in the G1, S or G2M phase of the cell cycle were
assessed.
As shown in Figure 2, upon exposure of SW1573 cells to a
low concentration of bortezomib, 10 nM, cells went into
G2M cell cylce arrest, whereas H460 cells remained pre-
dominantly in the G1 phase of the cell cycle. This finding
suggested that the proteasome activity in H460 cells is not
inhibited at 10 nM of bortezomib, as proteasome inhibi-
tion typically results in G2M arrest [18,19]. Furthermore,
G2M arrest in SW1573 and H460 cells was associated with
increased expression of Mcl-1, which is known to be
upregulated upon proteasome inhibition [15,20]. As
shown in Figure 2, Mcl-1 is only upregulated in H460 cells
when exposed to bortezomib at a high concentration (100
nM), whereas Mcl-1 is upregulated in SW1573 cells also at
a low concentration of bortezomib (10 nM). Concord-
antly, treatment with bortezomib 10 nM for 48 h led to
significant apoptosis in SW1573 cells (18%), but not in
H460 cells. However, at a higher dose of bortezomib (50
to 100 nM), both SW1573 and H460 cells went into G2M
arrest, resulting after 48 h in more apoptotic H460 cells
(49%) compared to SW1573 cells (32%). Thus, upon
effective induction of G2M cell cycle arrest, the apoptosis
inducing potential of bortezomib was more pronounced
Growth inhibition by bortezomib in NSCLC cells Figure 1
Growth inhibition by bortezomib in NSCLC cells. (A) Growth curves (MTT assays) of NSCLC cells treated with differ-
ent concentrations of bortezomib. Mean of at least three independent experiments, SD. (B) IC50 concentrations and p53 status 
of individual cell lines. Wt: wild type; mut: mutated.Molecular Cancer 2007, 6:73 http://www.molecular-cancer.com/content/6/1/73
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in H460 cells compared to SW1573 cells, indicating a dif-
ferent apoptotic phenotype. In contrast, SW1573 cells
went into G2M arrest at a lower threshold concentration
of bortezomib than H460 cells, also indicating a different
proteasomal phenotype of these two cell lines.
In order to further evaluate the mechanism of resistance to
bortezomib, proteasome activity was measured upon
treatment with various concentrations of bortezomib in
H460, SW1573 and H460-Bcl-2 cells. H460-Bcl-2 cells,
overexpressing anti-apoptotic factor Bcl-2, have a more
apoptosis resistant phenotype compared to the parental
H460 cells [15].
As shown in Figure 3, the basal level of proteasome activ-
ity was about 10% lower in SW1573 cells compared to
H460 and H460-Bcl-2 cells. Furthermore, at 10 nM of
bortezomib, proteasome inhibition occurred exclusively
in SW1573 cells. In contrast, at 100 nM of bortezomib the
level of proteasome inhibition was similar in all cell lines.
Overexpression of Bcl-2 did not alter the basal proteas-
ome activity nor its inhibition induced by bortezomib
[15].
These observations confirmed a differential proteasomal
phenotype comparing H460 and SW1573 cells and indi-
cate that the proteasomal phenotype is independent of
the apoptotic phenotype.
Bortezomib predominantly inhibits the chymotryptic-like
activity of the 20S proteasome, harboured in the β5 subu-
nit, and to a lesser extent the caspase-like activity har-
boured in the β1  subunit [21,22]. We therefore next
evaluated whether the relative sensitivity for proteasome
Induction of apoptosis and cell cycle arrest by bortezomib Figure 2
Induction of apoptosis and cell cycle arrest by bortezomib. (A) Effect of different concentrations of bortezomib on cell 
cycle progression of H460 and SW1573 cells upon 24 or 48 hours of exposure. Mean of at least three independent experi-
ments, SD. Ut: untreated. (B) Time and concentration course Western blot analysis of total cell extracts of H460 and SW1573 
cells showing the effect of treatment with bortezomib on the expression level of Mcl-1.Molecular Cancer 2007, 6:73 http://www.molecular-cancer.com/content/6/1/73
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inhibition of SW1573 cells correlated with a decreased
expression level of the 20S proteasome and its individual
catalytically active subunits, β1, β2 and β5. As shown in
Figure 3B, the expression level of the β1, β2 and β5subunits
was slightly increased in H460 cells compared to SW1573
after 24 h exposure to bortezomib (10, 100 nM). Addi-
tionally, exposure to bortezomib induced expression of
subunit β1 in H460 cells as compared to untreated con-
trol. In agreement with our results, increased expression of
proteasome subunits, as well increased (basal) proteas-
ome activity, was recently related to resistance to proteas-
ome inhibitor treatment [12].
To examine the possibility that apoptotic factors might
explain the differential sensitivity for apoptosis induction
once the proteasome has been effectively inhibited, we
assessed the expression of heat shock proteins, such as
Hsp27, Hsp70 and Hsp90 upon exposure of H460 and
SW1573 cells to bortezomib. Notably the expression of
Hsp27, but also Hsp90, was higher in SW1573 cells than
in H460 cells, correlating with less pronounced apoptosis
in SW1573 cells. The expression levels of Hsp70 was sim-
ilar in both cell lines.
NSCLC cell lines display differential sensitivity towards
the proteasome inhibitor bortezomib. For effective induc-
tion and execution of apoptosis at least two conditions
must be met. First, the dose of bortezomib must be above
the threshold necessary to inhibit the proteasome activity
in individual NSCLC cells. We showed that this threshold
concentration differs among non-small cell lung cancer
cells. Typically in clinical studies, proteasome inhibition
Proteasome activity and expression of catalytic subunits upon bortezomib treatment Figure 3
Proteasome activity and expression of catalytic subunits upon bortezomib treatment. (A) Intracellular proteas-
ome activity in H460, H460-Bcl-2 and SW1573 cells treated with a concentration range of bortezomib. Mean of at least three 
independent experiments, SD. (B) Time and concentration course Western blot analysis of total cell extracts of H460 and 
SW1573 cells showing the effect with treatment with bortezomib on the expression level of the 20S proteasome core (α/β), 
individual catalytic subunits: β1,β2, β5 and (C) heat shock proteins Hsp27, Hsp70 and Hsp90.Molecular Cancer 2007, 6:73 http://www.molecular-cancer.com/content/6/1/73
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in peripheral blood mononuclear cells is taken as a surro-
gate pharmacodynamic marker. These results indicate
however that this might not be a fair estimate of what is
occurring in the actual tumour tissue, as the proteasomal
phenotype of individual tumours is subject to significant
variability [23,24].
Secondly, upon inhibition of the proteasome, an intrinsic
or acquired resistance to apoptosis must be overcome, the
apoptotic phenotype being variable in different NSCLC
cell lines. In this regard, apoptosis resistance does not
directly correlate with resistance resulting from a differen-
tial proteasomal phenotype, as was shown in SW1573
cells, which were more sensitive to proteasome inhibi-
tion, but more resistant to apoptosis than H460 cells.
Additionally, H460 cells overexpressing anti-apoptotic
Bcl-2 showed a similar proteasomal phenotype as did
wild type H460 cells. Increased apoptosis resistance of
SW1573 cells compared to H460 cells might result from
increased expression of Hsp27 in SW1573 cells, which has
been postulated to be a resistance factor for bortezomib-
induced cell death [14].
It was recently suggested in a mice model of colon carci-
noma, that potentiation of the anticancer activity of bort-
ezomib by combination with TNF-α resulted from
reduced expression of proteasome subunits and inhibi-
tion of Hsp27 [25]. Breast carcinoma cells were shown to
be more resistant to treatment with bortezomib than nor-
mal breast cells, despite a higher level of feedback protea-
some upregulation in the normal cells. The authors
suggested resistance of the cancer cells compared to the
normal cells was primarily due to a defective pathway of
bortezomib-induced apoptosis in the cancer cells [11].
Another report suggested resistance to bortezomib can
occur in lymphoma cells through an altered proteasomal
phenotype coinciding with increased expression and
altered subunit composition of proteasome [12]. Our pre-
liminary results indicate that also H460 cells can adapt to
continuous incremental exposure of bortezomib (data
not shown).
Additionally, we recommend an assay allowing cell frac-
tion measurement, such as PI-staining based FACS analy-
sis, over an anti-proliferative assay, such as MTT, to
characterise the cytotoxic effects of proteasome inhibitors.
Cell fraction measurement by PI-staining based FACS
analysis is informative about the apoptosis inducing
potential (subG1 fraction) and inhibition of proteasome
activity (G2M arrest). In contrast, a low IC50(e.g. SW1573
cells), as determined by MTT assay, does not necessarily
correspond to enhanced apoptosis induction in a certain
cell line, compared to a cell line with a higher IC50 (e.g.,
H460 cells).
Our preliminary results show that the proteasomal as well
as apoptotic phenotype determines bortezomib sensitiv-
ity in NSCLC cells. There is a preclinical rationale to com-
bine proteasome inhibition with pro-apoptotic agents as
well as agents promoting a more favourable proteasomal
phenotype to overcome this resistance [20,26].
Materials and methods
Cell lines and drugs
NSCLC cell lines H292, H460, H1299, H322, A549,
H1703 and SW1573 were obtained from the American
Type Culture Collection (Manassas, VA, USA) and cul-
tured in RPMI1640 or, SW1573 only, DMEM (Cambrex
Bioscience, Verviers, Belgium). H460 cells stably overex-
pressing Bcl-2 (H460-Bcl-2) were generated previously
[27]. Culture mediums were supplemented with 10%
FCS, 100-units/ml penicillin, and 100-μg/ml streptomy-
cin (Invitrogen, Breda, The Netherlands). Bortezomib
(Velcade™) (Millennium Pharmaceuticals Inc. Cam-
bridge, MA, USA) was dissolved in DMSO.
Growth inhibition assay
Growth inhibition was determined 72 h after treatment
with a concentration range of bortezomib, by MTT assay,
as described previously [15]. Results are presented as per-
centage of survival taking the control (untreated cells) as
100% survival. The concentration resulting in 50% of cell-
growth inhibition (IC50) was calculated using SigmaPlot
version 8.0 software (SPSS Inc., Chicago, IL, USA).
Flow cytometric analysis of PI-stained cells
Propidium iodide (PI) staining and flow cytometry analy-
sis were performed as described previously [15]. The frac-
tion of cells with hypodiploid DNA content was
considered as the apoptotic cell population. Cell cycle
fractions were estimated using WinMDI Version 2.9 (The
Scripps Research Institute, La Jolla, CA, USA) and Cyl-
chred (Cardiff University, Cardiff, UK) version 1.0.2 soft-
ware.
Proteasome activity assay
The chymotryptic activity of the proteasome was esti-
mated as described previously [15], using succinyl-Leu-
Leu-Val-Tyr-AMC substrate (Bachem, King of Prussia, PA,
USA). Fluorescence of the released 7-amido-4-methylcou-
marin dye was measured on a SpectraFluor multiwell
plate reader (Tecan, Salzburg, Austria), set at an excitation
wavelength 380 nm and emission wavelength 460 nm.
Western blot analysis
Western blot analysis was performed as described before
[15]. Rabbit polyclonal antibodies used were: anti-Hsp70
(Affinity Bioreagents, Golden, CO, USA), anti-Hsp90
(Cell Signaling, Danvers, MA, USA), anti-20S proteasome
core, anti-subunit β1, β2, β5 (Biomol, Plymouth Meeting,Molecular Cancer 2007, 6:73 http://www.molecular-cancer.com/content/6/1/73
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PA, USA), anti-Mcl-1 (clone 22, BD PharMingen, San
Diego, CA, USA), mouse monoclonal antibodies used
were: anti-Hsp27 (Cell Signaling), anti-β-actin (Sigma-
Aldrich, St Louis, MO, USA).
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